Usefulness and safety of pasireotide in a case of acromegaly highly resistant to treatment.

Background: Pasireotide is a novel somatostatin analogue with higher affinity to 4/5 known human somatostatin receptors subtypes. It could have utility in acromegalic patients not responding to available treatments, although a deterioration in glucose metabolism is described during its use. Case: We describe our experience in the management of a case of a 41 years-old man affected by mixed GH-PRL secreting pituitary macroadenoma (32 mm) high resistant to different treatments. At baseline, the patient showed GH nadir after OGTT 26 ng/ml, IGF-1 1369 ng/dl, PRL 2386 ng/ml, normal glucose tolerance (NGT) with HbA1c 5.9%. Eight months of pre-operative treatment with monthly lanreotide LA 120 mg …

Utilizzo dell’insulina detemir in una casistica di donne affette da diabete tipo 1 in gravidanza: uno studio caso-controllo retrospettivo.

Monitoraggio ambientale dei gas anestetici: studio condotto in 20 sale operatorie di Ospedali palermitani